Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-11-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司2023年度向特定对象发行A股股票募集说明书（申报稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（申报稿）" which translates to "Prospectus (Filing Draft)" for a specific issuance of A shares by Jinling Pharmaceutical Company Limited. It contains detailed information about the company, the issuance plan, risk factors, financial impacts, and legal statements. The document is lengthy (15,000 characters) and includes comprehensive disclosures typical of a securities offering prospectus. It is not an annual report, earnings release, or management discussion, but rather a detailed capital raising document related to a specific share issuance. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. Therefore, the correct classification is CAP with high confidence.
2023-11-28 Chinese
金陵药业股份有限公司关于向特定对象发行股票的审核问询函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding updates to application documents related to a specific private placement of shares. It references responses to review inquiry letters from the Shenzhen Stock Exchange and updates to the prospectus for the private placement. The document discusses regulatory review processes and the need for approval from the China Securities Regulatory Commission before implementation. It does not contain financial statements or detailed financial data but rather updates on the application and regulatory review process for a capital raising event. Therefore, this is an announcement related to capital raising activities, specifically a Capital/Financing Update.
2023-11-28 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a specific issuance of A shares by Jinling Pharmaceutical Company Limited in 2023. It is issued by CITIC Securities as the sponsor for this specific share issuance. The content includes detailed information about the sponsor, the issuance type, company background, shareholder structure, and financial data relevant to the issuance. This document is clearly related to a capital raising event and the underwriting/sponsorship of a share issuance. It is not a general annual report, audit report, earnings release, or other types of filings. It is a detailed document supporting a capital/financing update, specifically a share issuance to specific investors. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the actual report, not just an announcement or certification.
2023-11-28 Chinese
关于金陵药业股份有限公司申请向特定对象发行股票的审核问询函之回复报告
Management Reports Classification · 95% confidence The document is a detailed reply report to a review inquiry letter from the Shenzhen Stock Exchange regarding a company's application for a specific object stock issuance. It contains extensive financial data, business analysis, market position, product pricing, cost trends, and performance comparisons for the years 2021, 2022, and the first nine months of 2023. The document is lengthy (15,000 characters) and includes comprehensive financial and operational information, indicating it is a substantive financial report rather than a brief announcement or certification. The content focuses on financial performance, business trends, and management's explanation of results and outlook, which aligns with the definition of a Management Reports (MDA) filing. It is not an Annual Report (10-K) or Interim Report (IR) because it is a reply to a regulatory inquiry about a specific financing event, providing detailed management analysis rather than a full annual or quarterly report. Therefore, the best classification is Management Reports (MDA).
2023-11-28 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to a 2023 specific object issuance of A shares by Jinling Pharmaceutical Company Limited. It contains detailed information about the issuer, the issuance plan, financial data, risk factors, and the underwriting institution's statements. The document is lengthy (15,000 characters) and includes comprehensive financial and operational data, risk disclosures, and issuance details. It is not a simple announcement or a brief summary but a detailed formal document related to a capital raising event. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER) because it focuses on the issuance of shares and related sponsorship, not on periodic financial results or management discussion. It is not a Regulatory Filing (RNS) because it is a substantive document, not a simple compliance or certification filing. Therefore, the best classification is Capital/Financing Update (CAP).
2023-11-28 Chinese
江苏泰和律师事务所关于金陵药业股份有限公司2023年度向特定对象发行A股股票的补充法律意见书（六）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's 2023 private placement of A shares. It references multiple supplementary legal opinion letters, regulatory inquiry letters from the Shenzhen Stock Exchange, and detailed legal and financial compliance checks related to the issuance. The content includes legal compliance, regulatory review responses, and detailed explanations of the issuance process and related financial data. This is not a full annual or quarterly financial report, nor is it an earnings release or a management discussion. It is a legal opinion document related to a capital raising event (private placement of shares). Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it pertains to the issuance of shares to specific investors and related legal opinions.
2023-11-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.